Transparent bones enable researchers to observe the stem cells inside – Medical Xpress

April 26, 2017 A mouse tibia that has been rendered transparent with Bone CLARITY. Stem cells appear distributed throughout the bone in red. The ability to see bone stem cell behavior is crucial for testing new osteoporosis treatments. Credit: Science Translational Medicine, Greenbaum, Chan, et al; Gradinaru laboratory/Caltech

Ten years ago, the bones currently in your body did not actually exist. Like skin, bone is constantly renewing itself, shedding old tissue and growing it anew from stem cells in the bone marrow. Now, a new technique developed at Caltech can render intact bones transparent, allowing researchers to observe these stem cells within their environment. The method is a breakthrough for testing new drugs to combat diseases like osteoporosis.

The research was done in the laboratory of Viviana Gradinaru (BS '05), assistant professor of biology and biological engineering and a Heritage Medical Research Institute Investigator. It appears in a paper in the April 26 issue of Science Translational Medicine.

In healthy bone, a delicate balance exists between the cells that build bone mass and the cells that break down old bone in a continual remodeling cycle. This process is partially controlled by stem cells in bone marrow, called osteoprogenitors, that develop into osteoblasts or osteocytes, which regulate and maintain the skeleton. To better understand diseases like osteoporosis, which occurs when loss of bone mass leads to a high risk of fractures, it is crucial to study the behavior of stem cells in bone marrow. However, this population is rare and not distributed uniformly throughout the bone.

"Because of the sparsity of the stem cell population in the bone, it is challenging to extrapolate their numbers and positions from just a few slices of bone," says Alon Greenbaum, postdoctoral scholar in biology and biological engineering and co-first author on the paper. "Additionally, slicing into bone causes deterioration and loses the complex and three-dimensional environment of the stem cell inside the bone. So there is a need to see inside intact tissue."

To do this, the team built upon a technique called CLARITY, originally developed for clearing brain tissue during Gradinaru's postgraduate work at Stanford University. CLARITY renders soft tissues, such as brain, transparent by removing opaque molecules called lipids from cells while also providing structural support by an infusion of a clear hydrogel mesh. Gradinaru's group at Caltech later expanded the method to make all of the soft tissue in a mouse's body transparent. The team next set out to develop a way to clear hard tissues, like the bone that makes up our skeleton.

In the work described in the new paper, the team began with bones taken from postmortem transgenic mice. These mice were genetically engineered to have their stem cells fluoresce red so that they could be easily imaged. The team examined the femur and tibia, as well as the bones of the vertebral column; each of the samples was about a few centimeters long. First, the researchers removed calcium from the bones: calcium contributes to opacity, and bone tissue has a much higher amount of calcium than soft tissues. Next, because lipids also provide tissues with structure, the team infused the bone with a hydrogel that locked cellular components like proteins and nucleic acids into place and preserved the architecture of the samples. Finally, a gentle detergent was flowed throughout the bone to wash away the lipids, leaving the bone transparent to the eye. For imaging the cleared bones, the team built a custom light- sheet microscope for fast and high-resolution visualization that would not damage the fluorescent signal. The cleared bones revealed a constellation of red fluorescing stem cells inside.

The group collaborated with researchers at the biotechnology company Amgen to use the method, named Bone CLARITY, to test a new drug developed for treating osteoporosis, which affects millions of Americans per year.

"Our collaborators at Amgen sent us a new therapeutic that increases bone mass," says Ken Chan, graduate student and co-first author of the paper. "However, the effect of these therapeutics on the stem cell population was unclear. We reasoned that they might be increasing the proliferation of stem cells." To test this, the researchers gave one group of mice the treatment and, using Bone CLARITY, compared their vertebral columns with bones from a control group of animals that did not get the drug. "We saw that indeed there was an increase in stem cells with this drug," he says. "Monitoring stem cell responses to these kinds of drugs is crucial because early increases in proliferation are expected while new bone is being built, but long-term proliferation can lead to cancer."

The technique has promising applications for understanding how bones interact with the rest of the body.

"Biologists are beginning to discover that bones are not just structural supports," says Gradinaru, who also serves as the director of the Center for Molecular and Cellular Neuroscience at the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech. "For example, hormones from bone send the brain signals to regulate appetite, and studying the interface between the skull and the brain is a vital part of neuroscience. It is our hope that Bone CLARITY will help break new ground in understanding the inner workings of these important organs."

The paper is titled "Bone CLARITY: Clearing, imaging, and computational analysis of osteoprogenitors within intact bone marrow."

Explore further: Growing new bone for more effective injury repair

More information: Alon Greenbaum et al, Bone CLARITY: Clearing, imaging, and computational analysis of osteoprogenitors within intact bone marrow, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aah6518

Broken bones do not always repair fully, especially after major trauma such as a car accident. Complications can occur when the bone is broken in several places, the blood flow is reduced or infection sets in. Patients can ...

An international team of researchers, funded by Morris Animal Foundation, has shown that adipose (fat) stem cells might be the preferred stem cell type for use in canine therapeutic applications, including orthopedic diseases ...

Researchers at the University of Illinois report they can alter blood cell development through the use of biomaterials designed to mimic characteristics of the bone marrow.

A team of scientists at the Children's Research Institute at UT Southwestern (CRI) has become the first to use a tissue-clearing technique to localize a rare stem cell population, in the process cracking open a black box ...

Stem cells in bone marrow need to produce hydrogen sulfide in order to properly multiply and form bone tissue, according to a new study from the Center for Craniofacial Molecular Biology at the Herman Ostrow School of Dentistry ...

Ten years ago, the bones currently in your body did not actually exist. Like skin, bone is constantly renewing itself, shedding old tissue and growing it anew from stem cells in the bone marrow. Now, a new technique developed ...

Regenerative medicine using human pluripotent stem cells to grow transplantable tissue outside the body carries the promise to treat a range of intractable disorders, such as diabetes and Parkinson's disease.

Scientists have long thought that calcium transport into mitochondria - the powerhouses of cells - is a key signal linking cardiac workload, or how hard the heart pumps, with energy production. Studies at the Lewis Katz School ...

Using a unique microscope capable of illuminating living cell structures in great detail, researchers at the University of Colorado Anschutz Medical Campus have found clues into how a destructive autoimmune disease works, ...

Your brain needs just the right balance between excitatory "on" signals and inhibitory "calm down" signals. Now scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown that a protein helps balance ...

Humans, like virtually all other complex organisms on Earth, have adapted to their planet's 24-hour cycle of sunlight and darkness. That circadian rhythm is reflected in human behavior, of course, but also in the molecular ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More here:
Transparent bones enable researchers to observe the stem cells inside - Medical Xpress

Custer considered for stem cell study | The Miami Student – Miami Student

WSU student fractured spine at Oxford party

Ryan Custer, a Wright State University student who was severely injured at an Oxford party, is being considered for a stem cell study at Rush University Hospital in Chicago. The 19-year-old, a first-year forward for the Raiders varsity basketball team, will be evaluated for five days before doctors determine if he qualifies for the study.

Custer suffered a severe spinal injury after jumping into a makeshift pool at a party on S. Main Street on Saturday, April 8. Custer collided with another persons knee when he slid into the pool, causing the injury. Custer was immediately transported to the University of Cincinnati Medical Center where he underwent surgery on his spine that night.

Feeling in Custers legs has not returned, and he has only recently regained some movement in his fingers.

Custer was transported from the UC Medical Center to Rush Hospital on Sunday, April 22. According to a post from the Ryan Custer Recovery Care Page, a Facebook page updated almost daily by Custers family, he spent the first day in Chicago getting acclimated in his new room in Rushs ICU and meeting the doctor who will lead the study, Dr. Richard Fessler.

Dr. Fessler, a renowned spinal surgeon, has focused his research on developing and refining new ways to perform minimally invasive spinal surgeries. In 2010, Fessler performed surgery on former Indianapolis Colts quarterback Peyton Manning, which Custer was happy to learn, the post said.

The five-day period of testing began Monday, and, if selected for the study, treatment for Custer will begin on Friday. The study, called the SCiStar study, will evaluate how the injection of AST-OPC1, particular neural cells produced from human embryonic stem cells, at a single time 14 to 30 days after an injury can benefit the patients recovery.

According to the SCiStar webpage, the studys researchers are seeking adults between the ages of 18 and 69 who recently experienced a spinal cord injury in the neck which resulted in a loss of feeling below the site of the injury in addition to some paralysis in the arms and legs.

HBO has contacted Dr. Fessler about following a patient through this research process.

Ryan thinks it would be cool to do it, so we said yes,an April 22 Facebook post reads. Another step in the plan God has mapped out for Ryan.

A fundraising page created for Custer, The Ryan Custer 33 Recovery Fund, is close to raising its entire $100,000 goal. At the time of publication, the fund was just about $4,000 shy of the 100k mark.

Over 6,500 people have liked the page and are following along with Custers recovery through the familys Facebook updates.

View original post here:
Custer considered for stem cell study | The Miami Student - Miami Student

We need a new NIH director: Column – USA TODAY

David A. Prentice 6:04 a.m. ET April 25, 2017

Francis Collins speaks to the USA TODAY Editorial Board in 2014.(Photo: Jack Gruber, USA TODAY)

Over his first 100 days in office, President Trump has set a new direction for the country in a variety of areas, from Defense policy to health care and federal hiring.One by one, he has been making good on his campaign promises.He is burnishing his pro-life credentials as well as proving his drive to innovate and put America back in a position of global leadership.Next on the presidents list should be a new director for the National Institutes of Health (NIH).

The incumbent, Dr. Francis Collins, is a leftover from the Obama administration.That is startling enough for such a vital role, but Collins is most definitely not pro-life nor in the same leadership class as Trump.Collins left the NIH in 2008 to work for the Obama campaign team, where he helped set the Obama research priorities, including creating the NIH registry of human embryonic stem cell lines. The registry is a listing of cells created by destroying human embryos that are eligible for federal taxpayer dollars, and the power to approve for this deathly listing rests with the NIH director.

Collins also supports human cloning to create embryos for experiments.Some call such a technique clone and kill since the cloned human embryo is not allowed to survive and develop, but is disaggregated to use her cells in laboratory tests.

He takes the completely unscientific view that a cloned embryo is not really an embryo, because, he says, this is not the natural way that embryos come into existence.This makes any cloned human beings fair game to be used, including destroyed, for experiments.By Collins logic, Dolly the cloned sheep was not really a sheep.

Democrats aren't the party of science: Jonah Goldberg

Why I march for life: Column

Unethical research under the Collins-led NIH doesnt stop there.In 2016, NIH began consideration of allowing creation with taxpayer dollars of human-animal chimeras,including creation of animals that could contain human sperm, human eggsor a human brain. This macabre, unethical science certainly does not represent innovation in healthcare.

Even though we are now in the Trump era, Collins continues to approve more cell lines from destroyed human embryos for use intaxpayer-funded research; the most recent approvals were last month.Embryonic stem cell science relies on destroying embryos to harvest their cells.Collins not only approves of this technique but continues to award federal dollars to the destroyers of young embryos.He has called it important, life-saving research, despite the fact that embryonic stem cells have not saved a single human life nor had any proven success in patients.Its all about destruction and lives lost.

POLICING THE USA:Alook atrace, justice, media

We're scaring off future Einsteins: USD president

Personnel, the adage goes, is policy.Leftovers represent stale policy.Trump needs someone in this critical leadership role for American research who aligns with his strong pro-life ethic and his desire to unleash American ingenuity.There arewell-qualified candidates to rev up Americas biomedical engine and to make it a fountainhead of new therapies against some of the worst diseases facing our world.

In this enterprise, we havent a moment to lose.We just need a new NIH Director.

David A. Prentice is vice president & director of research at Charlotte Lozier Institute, research and education institute of the Susan B. Anthony List, an organization dedicated to electing candidates and pursuing policies that will reduce and ultimately end abortion..

You can readdiverse opinions from ourBoard of Contributorsand other writers ontheOpinion front page,on Twitter@USATOpinionand in our dailyOpinion newsletter.To respond to a column, submit a comment toletters@usatoday.com.

Read or Share this story: http://usat.ly/2pZSabK

Read more:
We need a new NIH director: Column - USA TODAY

California’s deadly ‘social legislation’ parallels its economic and political death spiral – Desert Dispatch

By Richard Reeb

The Golden States well-known descent from its years of prosperity and political clout, which stands in sharp contrast to the nations recently renewed growth and turn to the right, has another side. That is its Democrat leaders determination to facilitate the death of unwanted unborn babies, the elderly and terminally ill. Indeed, this session of the California State Legislature provides more evidence of this ominous trend.We Californians already legalize and finance abortion on demand and last year sanctioned so-called assisted suicide. Now attention is turning to new means and new victims of this misguided movement.In the State Senate, four bills have been introduced to this end, while one constitutional amendment has been proposed to stem the billions in funding for embryonic stem cell research.First, the bill (SB 743) of Sen. Richard Pan, D-Sacramento, would guarantee that Planned Parenthood and other abortion providers could still receive federal Medicaid funds via Medi-Cal family planning services. This is a perfect example of California Democrats defiance of the national conservative trend. Fortunately, it will probably go nowhere as President Donald Trump has recently rescinded his immediate predecessors executive order to force states to finance abortions.Exemplifying abortion advocates virtual sanctification of fetal homicide is SB 309, originally introduced by Sen. Pan, which would actually establish a specialty license plate celebrating reproductive freedom. Revenue generated would go to the California Reproductive Freedom Fund, whatever that is.One wonders: did the Third Reich authorize plates for Volkwagens to celebrate the killing of members of inferior races?Sen. Pans SB 481 would allow nursing homes to declare patients unfit to make their own decisions, and then implement medical procedures which may include assisted suicide. The state already permits persons believed to be facing deathin six monthsto end their lives, justified on the grounds of their own consent. This new development demonstrates just how hollow that premise was.While unlikely to make it out of committee, Senate Constitutional Amendment 7 would repeal the (embryonic) Stem Cell Research and Cures Act approved by the states voters in 2004. That misguided measure was sold on the failed promise that embryonic cells offered the greatest potential. But experience with adult stem cells and from placentas has been far more fruitful.Though not directly aimed at death, SB 18, also the work of Sen. Pan, originally sought to challenge parental authority in the name of childrens rights. Of course, parents natural concern for their childrens very lives cannot be surpassed. Yet this bill would have directly threatened parents ability to provide in-home education for their children or to send them to private schools.But Senate committee action has changed the focus of the bill to establish an 18-member Children and Youth joint committee (half from the Senate and half from the Assembly) to direct the legislature to maximize spending on that class of persons. It would undo current code on this subject by the year 2025. The original alarming objectives doubtless will be implemented in bits and pieces through the new committees efforts. Do only children who have been permitted to be born deserve this intense concern?Meanwhile, California's new Attorney General Xavier Becerra has slapped 15 felony charges 14 counts of illegally recording conversations without consent and one count of conspiracy against David Daleiden, the project lead at the Center for Medical Progress (CMP), and his associate Sandra Merritt.In the past 20 months, the Center for Medical Progress has released a series of undercover videos that feature high end Planned Parenthood officials and employees of tissue procurement companies associated with the nation's largest abortion provider. They admitted in recorded conversations various illegalities about how the companies skirted state and federal law to engage in the selling of highly-desired aborted baby tissue, organs and limbs."At the end of the day, the only thing that is different from the work that I did and the work that CMP did and the work that undercover journalists and investigative journalists are doing every single day here in California ... is who I went after," Daleiden said during a telephone interview with the Washington Times."The only difference is that I happened to go after and expose the political ally and financial backers of the establishment power structure in California and in the country. That is the only reason why I am being prosecuted with these bogus charges under California Penal Code 632 and why the local reporters with NBC Los Angeles and other places are not. That really says it all."One can only hope that Californias political leadership would be as zealous in saving lives as they are in ending them. But alas they are not. Such is the situation in our coming sanctuary state.

Richard Reeb taught political science, philosophy and journalism at Barstow College from 1970 to 2003. He is the author of "Taking Journalism Seriously: 'Objectivity' as a Partisan Cause" (University Press of America, 1999). He can be contacted at rhreeb@verizon.net

See the article here:
California's deadly 'social legislation' parallels its economic and political death spiral - Desert Dispatch

Drugs already in medicine cabinets may fight dementia, early data suggests – Ars Technica

Enlarge / Oh, there's that cure I was looking for.

Tried, true, and FDA-approved drugs for cancer and depressionalready in medicine cabinetsmay also be long-sought treatments for devastating brain diseases such as Alzheimers, Parkinsons, and other forms of dementia, according to a new study in Brain, a Journal of Neurology.

The research is still in early stages; it only involved mouse and cell experiments, which are frequently not predictive of how things will go in humans. Nevertheless, the preliminary findings are strong, and scientists are optimistic that the drugs couldone day help patients with progressive brain disease. Researchers are moving toward human trials. And this process would be streamlined because the drugs have already cleared safety tests. But even if the early findings hold up, it would still take years to reach patients.

In the preliminary tests, the two drugstrazodone hydrochloride, used to treat depression and anxiety, and dibenzoylmethane (DBM), effective against prostate and breast tumorscould shut down a devastating stress response in brain cells, known to be critical for the progression of brain diseases. The drugs both protected brain cells and restored memory in mice suffering from brain diseases.

"We're excited by the potential of these findings from this well-conducted and robust study, Doug Brown, of the Alzheimer's Society, told the BBC.

David Dexter, from Parkinson's UK, added that if these studies were replicated in human clinical trials, both trazodone and DBM could represent a major step forward.

For years, researchers have known that a stress response in cells, called unfolded protein response, or UPR, is involved in a bunch of neurodegenerative diseases. The response kicks in when theres a buildup of unfolded or misfolded proteins. Typically, protein chains are folded into specific 3D structures that are often critical for their function in the body. But this folding goes awry in some neurodegenerative conditions, such as prion diseases, Alzheimer's disease, Parkinson's disease, and other forms of dementia.

When this happens, UPR kicks in. It shuts down protein production, tries to junk the botched proteins, and gets protein production machinery back in order. If all goes well, the cell can resume normal protein production. But if it doesnt, UPR initiates apoptosis, aka cell suicide.

In neurodegenerative diseases, things dont go well; UPR is over-activated, and brain cells start dying off. Scientists know that hampering UPR can protect brain cells and restore memory in mice engineered to mimic having Alzheimer's disease. But so far, all the compounds found to knock back UPR were highly toxic or highly insoluble (they dont work as medicine).

For a drug discovery shortcut, researchers at the University of Cambridge wondered: do we already have drugs that can interfere with UPRbut just dont know it? They screened a library of 1,040 FDA-approved drugs to find out.

Because UPR is highly conserved across animals, the researchers could use worms to screen the drugs. They initially found 20 drugs that seemed to have UPR-dampening effects. Upon further testing, they whittled down the list to five, then to two.

In further cell experiments, both trazodone and DBM inhibited a specific step in UPR and restored protein production. In mice, the drugs traversed the blood-brain barrier. When the researchers infected mice with a prion disease, clinically relevant doses of either drug held back neurological symptoms, boosted survival, and substantially reduced loss of brain cells in most of the infected mice. In mice that modeled a type of dementia, called frontotemporal dementia, both drugs could rescue the rodents memory and restore protein synthesis in brain cells.

The two drugs were markedly neuroprotective, the authors conclude. These drugs therefore represent an important step forward in the pursuit of disease-modifying treatments for Alzheimers and related disorders.

Trazodone, the authors note, is even already approved for use in the elderly. Clinical trials are the next step.

Brain, 2017. DOI: 10.1093/brain/awx074 (About DOIs).

The rest is here:
Drugs already in medicine cabinets may fight dementia, early data suggests - Ars Technica

SUPERHUMANS: Mars ‘will be colonised by genetically engineered Star Trek-style beings’ – Express.co.uk

GETTY STOCK IMAGE

The way to the Red Planet and other mysterious worlds is being inspired by the villainous Khan from the blockbuster films, according to new research.

The use of stem cell technology may mean the difference between life and death on any attempt to travel beyond Earth into the wilderness of space.

So the first person to walk on Mars is likely to be selected from the growing group of people whose parents took the step to store their child's stem cells at birth.

Stem cells are 'blank' cells that can be reprogrammed to turn into any other cell in the body, enabling the replacement of damaged cells.

More and more British parents, including TV presenter Natalie Pinkham and dancer Darcey Bussell, are paying more than 2,000 to freeze samples from their babies' umbilical cords at birth.

Stem cells are also found in bone marrow and some body tissue, but the procedure to harvest them from umbilical cords is less risky.

Adventurous Mars pioneers will have to be especially prepared for the dangerous trip, which could expose them to cancer and other diseases, through carefully researched gene therapy.

1 of 16

We wince at the thought of genetically engineered humans

Mark Hall

Mark Hall, spokesperson for the UK's leading stem cell storage and diagnostics company StemProtect, said: "We wince at the thought of genetically engineered humans.

"And we are not going to create a Khan from Star Trek specifically to get to another planet. Getting humans to Mars and beyond will be both expensive and dangerous.

"But the scientific by-products - such as huge leaps in stem cell medicine - will benefit humanity for centuries to come."

Genetic engineering has featured in two Star Trek movies, and a number of TV episodes.

IG

1 of 14

This still image strikes an uncanny resemblance to a figure of a woman

Khan, who appeared in Space Seed and Star Trek II: The Wrath of Khan, was modified to make him stronger and to give him greater stamina and intellectual capacity than a regular human.

Mr Hall said: "The first human to walk on Mars may not even be born yet - but that's an advantage."

StemProtect believes advanced medical techniques will be required to cope with the rigours of interplanetary space.

While a trip to Mars may appear "just around the corner" in galactic terms, it is highly possible exposure to radiation along the way could lead to the astronauts developing leukaemia and other cancers even before they arrived.

GETTY STOCK IMAGE

This means future travellers will have to be 'immunised' before they leave Earth.

Mr Hall said: "There was an article in The Times suggesting elephants would make ideal Martian travellers because they'd be largely immune to the radiation.

"But those laughing at the ridiculous sounding headline completely missed the point - the fact is scientists are already working on ways of getting humans there and back alive."

Recent research has shown radiation in deep space increase the risk of leukaemia while long term exposure to micro gravity may leave astronauts open to infection.

The three year round trip to Mars would affect humans at the stem cell level, leaving them with a drastically lowered immune system, NASA funded scientists say.

And NASA's own findings say stem cells may be crucial to the future of space travel, particularly how they respond in a low gravity environment.

One study showed stem cells flown in space and then cultured back on Earth had greater ability to self renew and generate any cell type, changing more easily into specialised heart muscle cells, for instance.

Mr Hall said an astronaut will have to be prepared for the journey "quite literally at the stem cell level."

He explained: "That means working with the best and most effective stem cells available to the patient - those harvested from the umbilical cord at birth."

GETTY STOCK IMAGE

The therapies required to 'immunise' humans to space travel are still being researched.

And with most space based science, it can only mean huge benefits to mankind back down on Earth when it comes to fighting otherwise deadly conditions and diseases.

Stem cells have the ability to treat a potentially infinite range of illnesses and diseases.

Stem cell therapy is already being used all over the world to treat some cancers and stroke victims - and there is fast progress being made in many other areas, including Parkinson's and Alzheimer's disease.

Read the rest here:
SUPERHUMANS: Mars 'will be colonised by genetically engineered Star Trek-style beings' - Express.co.uk

Nanovaccine shows potential as immunotherapy for cancer – Medical News Today

For the first time, researchers have shown that using a nanovaccine to deliver cancer immunotherapy can slow tumor growth and prolong survival in mouse models of several types of cancer.

The team - from the University of Texas Southwestern (UTSW) Medical Center in Dallas - describes the work in the journal Nature Nanotechnology.

Immunotherapy is a way of treating disease by getting the body's immune system to fight it.

When that disease is cancer, it is "critically important" that the immunotherapy generates immune cells called T cells that can recognize and target tumor cells for elimination.

One way to do this is to apply the principle of a vaccine, where antigens - molecules that uniquely identify the target - are delivered to the immune system to prime it to recognize and destroy the disease-causing cells.

Co-senior author Jinming Gao, a UTSW professor of pharmacology and otolaryngology, says that various established vaccine approaches - such as using live bacteria as the delivery mechanism - have been used in cancer immunotherapy.

However, he notes that these tend to be complex and costly, and they can also result in immune-related side effects.

The approach that the UTSW researchers have developed - which they describe as a "minimalist nanovaccine" - comprises a simple mixture of a tumor antigen and a synthetic polymer nanoparticle.

Nanoparticles are being increasingly used in medicine as they allow scientists to manipulate materials at the level of individual atoms, which is a very useful scale for tackling disease inside cells.

A significant advantage of UTSW's nanovaccine approach is that the nanoparticles take the antigen directly to the lymph nodes to help generate primed T cells.

Prof. Gao says that conventional vaccines do not do this - they require the immune cells to collect the antigens in a "depot system" first and then transport them to the lymph nodes to prime the T cells.

For the vaccine to work, it has to first deliver the antigens into a type of immune cell called an antigen-presenting cell. The antigen-presenting cells process and present the antigens for recognition by the T cells.

The process of priming the immune response is not simply a case of delivering the antigen. At the same time, there has to be a signal that also triggers the immune response to use the antigen.

The researchers note that their experimental nanovaccine does this by triggering an adaptor protein called STING.

Co-senior author Zhijian J. Chen, professor of molecular biology at UTSW, sums up how their nanovaccine performs all the necessary steps:

"For nanoparticle vaccines to work, they must deliver antigens to proper cellular compartments within specialized immune cells called antigen-presenting cells and stimulate innate immunity. Our nanovaccine did all of those things."

The team tested the nanovaccine on a variety of mouse models of cancer, including colorectal cancer, melanoma, and HPV-associated head, neck, cervix, and anogenital cancers. They note that in nearly all cases, the treatment led to slower tumor growth and prolonged survival.

The researchers are now teaming up with UTSW doctors to look at how to use the new nanovaccine in the clinic for a variety of cancers.

They believe that it is also possible to increase the anti-tumor effectiveness of the treatment by combining it with other immunotherapies, radiotherapy, and checkpoint inhibitors.

"What is unique about our design is the simplicity of the single-polymer composition that can precisely deliver tumor antigens to immune cells while stimulating innate immunity. These actions result in safe and robust production of tumor-specific T cells that kill cancer cells."

Prof. Jinming Gao

Learn about the recent discovery of thousands of rare cancer-related gene mutations.

Read more from the original source:
Nanovaccine shows potential as immunotherapy for cancer - Medical News Today

SAVSU and TrakCel announce collaboration to integrate Cell … – PR Newswire (press release)

TrakCel's Cellular Orchestration platform facilitates efficiency and compliance to quality standards in cell therapy manufacturing by enabling program-critical information to be collated, tracked and and documented. Detailed processes and managed workflows for every participant in the value chain enable safe and efficient scaling outward and upward as production increases. Conditional logic workflows for all participants including clinicians, logistics and manufacturing partners ensure standardization andcompliance with validated procedures.

Bruce McCormick, President of SAVSU Technologies, remarked, "Our optimized technologies represent the next generation of integrated, cloud-connected cold chain technologies. We are very pleased to collaborate with TrakCel and look forward to integrating our respective data platforms to provide even more value to our mutual customers. We are committed to driving a paradigm shift away from traditional, risk-laden cold chain practices based on the use of poor performing shipping containers and disconnected data systems."

Ravi Nalliah, CEO at TrakCel, commented, "We scoped the packaging and cold chain technologies space to identify best of breed ecosystem partners. SAVSU is so far ahead of traditional container and data logger suppliers, and we are very keen to integrate their innovations into our Cell Orchestration Platform. The timing of this collaboration is perfect as the cell therapy market continues to mature and awareness is peaked on the need to use better tools to enable clinical trial success, commercial scale-out, and reimbursement supported by evidence of compliance throughout manufacturing, distribution and patient administration."

Chain Link Research and Pharmaceutical Commerce market research estimate that there are 80 million to 130 million annual temperature sensitive pharmaceutical shipments requiring cold chain management, resulting in $12 billion spent annually on cold chain logistics, with $9 billion for transportation and $3 billion for specialized tertiary packaging and instrumentation such as insulated boxes, blankets, phase change materials, temperature sensors and data loggers. The use of currently available cold technologies results in $15 billion to $35 billion spent annually replacing products lost due to temperature excursions.

About SAVSU Technologies SAVSU is a leading designer and manufacturer of innovative, high performance, cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials.

For more information please visit http://www.savsu.com.

About TrakCel TrakCel's cell, gene and immunotherapy management solution improves clinical study efficacy and accelerates global scale-up and scale-out by implementing communications technology to integrate the delivery path from needle-to-needle. The technology provides interactive instructions to professionals across the supply chain and gives stakeholders on-demand visibility of procedural results and chain-of-custody data for immediate traceability, validation and compliance audits.

TrakCel technology is increasingly being adopted by leaders in the cell, gene and immunotherapy industry. TrakCel is headquartered in Cardiff, Wales with a U.S. offices in Newport Beach, California and Bridgewater, NJ.

For more information please visitwww.trakcel.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/savsu-and-trakcel-announce-collaboration-to-integrate-cell-therapy-manufacturing-and-cold--chain-data-management-platforms-300444497.html

SOURCE SAVSU Technologies

http://www.savsu.com

Original post:
SAVSU and TrakCel announce collaboration to integrate Cell ... - PR Newswire (press release)

Regenerative cell therapy, tissue engineering are future treatments – ModernMedicine

Reviewed by Jodhbir S. Mehta, PhD

There have beenmajor changes in the way keratoplasty has been performed over the past 15 years.

Data from the Singapore Corneal Transplant Study shows there have been improved outcomes in the lamellar surgical techniques compared to the full thickness penetrating keratoplasty (PK). However, different centers and different registries have reported different results.

Data published in 2014 inOphthalmology1showed worse outcomes with lamellar surgery compared to penetrating keratoplasty. It is important to look at registry data, which is from multiple surgeons.

A study, published last year inPLOSOne2, compared PK to anterior lamellar keratoplasty (ALK) and endothelial keratoplasty (EK), looking at graft failure outcomes. In all of the multiple studies, there was no statistical significance when looking at failure. This highlights the importance of good training programs to try to improve outcomes.

With EK, there are two difficulties with the surgical procedure. One is donor preparation and the other is graft insertion. Upfront, there are good options for outsourcing the donor preparation to eye banks.

How muchdamage?

The problem with graft insertion is there is no way to know, at the time of surgery, how much damage is being done to the endothelium. That can only be assessed 1 to 3 months postoperatively through specular microscopy, or confocal microscopy once the baseline edema clears.

Physicians at the Singapore National Eye Center have developed a calcein AM staining system, called CAM, which they use with an adapted Spectralis HRA confocal scanning laser ophthalmoscope (Heidelberg Engineering). This allows the surgeon to immediately look at the amount of damage on the whole graft being prepared for EK surgery. Even as methods improve, this will not solve the worldwide problem with donor retrievals.

A survey of 95% of the worlds transplant data shows that for every one cornea transplanted, there are 70 people needing corneal transplantation, and that out of about 284,000 corneas that are harvested per year, only 185,000 are used. Of the almost 100,000 not used, 30% are lost because of positive serology, but 60% was lost because of low endothelial cell count.

The leading indications for endothelial surgery are Fuchs dystrophy, bullous keratopathy, and corneal regrafting. In the future, regenerative medicine may be the approach for Fuchs. The approach to treating bullous keratopathy will include tissue engineering and cell therapy, and tissue engineering will be used for regrafting as well.

Read more:
Regenerative cell therapy, tissue engineering are future treatments - ModernMedicine

Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting – Business Wire (press release)

NEW YORK--(BUSINESS WIRE)--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells, today announced that data on its gene-edited allogeneic off-the-shelf CAR T-cell immunotherapies (UCART) will be presented at the ASGCT 20th Annual Meeting. The meeting will be held from May 10th to 13th, 2017 in Washington, D.C., USA.

Oral presentation:

Development of Gene Edited Allogeneic CAR T-Cell Therapy Philippe Duchateau, PhD. Chief Executive Officer, Cellectis

Session: 300 - Clinical Advancement of Gene Editing-Moving New Science to the Clinic - Organized by the Clinical Trials and Regulatory Affairs Committee

Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST Lincoln 2, 3, 4

Poster presentations:

176 - Genome-Wide Analysis of TALEN Activity in Primary Cells Brian Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent Poirot

Session: Gene Targeting and Gene Correction I Wednesday May 10, 2017 at 5:30 PM EST Exhibit Hall A & B South

114 - UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting CD22 with CAR T-cells Anne-Sophie Gautron, Ccile Schiffer-Mannioui, Alan Marechal, Severine Thomas, Agnes Gouble, Laurent Poirot, Julianne Smith

Session: Cancer-Immunotherapy, Cancer Vaccines I Wednesday May 10, 2017 from 5:30 PM to 7:30pm EST Exhibit Hall A & B South

372 - Manufacturing of Gene-Modified Mouse CAR T-Cells Laurent Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau

Session: Gene Targeting and Gene Correction II Thursday May 11, 2017 from 5:15 PM to 7:15 PM EST Exhibit Hall A & B South

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The companys mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN products and meganucleases as well as its pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis goal is to create innovative products in multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: http://www.cellectis.com

Talking about gene editing? We do it. TALEN is a registered trademark owned by the Cellectis Group

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Companys objectives based on the current expectations and assumptions of the Companys management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

Link:
Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting - Business Wire (press release)